DEFENCE THERAPEUTICS TO FINALIZE ITS
OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST
CANCER
Vancouver, BC,
Canada, September 29th,
2021 -
InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF ("Defence"
or the "Company"),
a biotechnology Company working on cancer therapeutics and
infectious diseases vaccines, is pleased to announce that it will
be conducting a series of final studies to complete all requirement
needed to initiate a Phase I trial for one of its leading AccuTOX
candidate against breast cancer.
The
AccumTM
technology platform was
initially designed to enhance the accumulation of specific
proteins, antibodies (ADCs) or antigen in target cells. Studies
conducted by Defence revealed a strong therapeutic function for
AccumTM
when delivered on its
own. In other words, the delivery of free "naked"
AccumTM
(AccuTOX-001) triggered
cell death of a variety of cancer cells, including breast cancer,
and was well tolerated by animals under the same treatment
regiment.
"We are actively
pursuing our AccuTOX program to initiate a Phase I trial against
breast cancer in Q1-Q2 of 2022" said Sebastien Plouffe, CEO of
Defence Therapeutics. "We will re-enforce our data by showing how
potent is AccuTOX-001 at killing of breast cancer in various animal
models including the use of patient-derived xenografts (PDX). The
secondary objectives would be to compare the potency of AccuTOX-001
as stand-alone or combination therapy with currently used
immune-checkpoint inhibitors", he added
The Defence team is
currently working to demonstrate that AccuTOX-001 can trigger the
death of pre-establish 4T1 breast cancer in immunocompetent mice
alone or in combination with anti-PD1. In parallel, the potency of
the leading drug will be demonstrated in previously characterized
PDX models to ensure a good translation from mice to human studies.
Once completed, this data along with the GLP study scheduled in Q4
of 2021 will be compiled and presented to the FDA to have clearance
for a Phase I trial against breast cancer.
Defence continues
extensive research and development programs with its
AccumTM
technology platform
including the AccuTOX program. Defence has developed a DC cancer
vaccine targeting 4 different indications (AccuVAC-D), two ADCs in
late-stage pre-clinical development (AccuADC) and various
protein-based vaccines against infectious diseases such as COVID
and HPV (AccuVAC-PTs and AccuVAC-INs).
In line with the
Company's strategy for preparing a Nasdaq listing submission in the
beginning of second quarter of 2022, Defence Therapeutics has
retained Lifewater Media to introduce Defence and its products to
the US investment community. The contract with Lifewater Media
begins for a 30-day period, starting at $150,000 USD. Lifewater
Media are well known professionals in the media industry with more
than 40 years of combined experience. Lifewater Media is a pioneer
in US marketing strategy and digital marketing.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells by inducing their entrapment
escape. As a result, increased efficacy and potency can be reached
against catastrophic illness such as cancer and infectious
diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.